Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neurosciences, King's College London, London, UK.
Diabetes Centre, King's College Hospital NHS Foundation Trust, London, UK.
Diabet Med. 2020 Oct;37(10):1658-1668. doi: 10.1111/dme.13918. Epub 2019 May 7.
We examined the effectiveness of a service innovation, Three Dimensions for Diabetes (3DFD), that consisted of a referral to an integrated mental health, social care and diabetes treatment model, compared with usual care in improving biomedical and health economic outcomes.
Using a non-randomized control design, the 3DFD model was offered in two inner-city boroughs in London, UK, where diabetes health professionals could refer adult residents with diabetes, suboptimal glycaemic control [HbA ≥ 75 mmol/mol (≥ 9.0%)] and mental health and/or social problems. In the usual care group, there was no referral pathway and anonymized data on individuals with HbA ≥ 75 mmol/mol (≥ 9.0%) were collected from primary care records. Change in HbA from baseline to 12 months was the primary outcome, and change in healthcare costs and biomedical variables were secondary outcomes.
3DFD participants had worse glycaemic control and higher healthcare costs than control participants at baseline. 3DFD participants had greater improvement in glycaemic control compared with control participants [-14 mmol/mol (-1.3%) vs. -6 mmol/mol (-0.6%) respectively, P < 0.001], adjusted for confounding. Total follow-up healthcare costs remained higher in the 3DFD group compared with the control group (mean difference £1715, 95% confidence intervals 591 to 2811), adjusted for confounding. The incremental cost-effectiveness ratio was £398 per mmol/mol unit decrease in HbA , indicating the 3DFD intervention was more effective and costed more than usual care.
A biomedical, psychological and social criteria-based referral system for identifying and managing high-cost and high-risk individuals with poor glycaemic control can lead to improved health in all three dimensions.
我们研究了一种服务创新,即“糖尿病三维(3DFD)”,该创新包括转介至综合心理健康、社会关怀和糖尿病治疗模式,与常规护理相比,以改善生物医学和健康经济效益。
采用非随机对照设计,3DFD 模型在英国伦敦的两个内城区实施,那里的糖尿病健康专业人员可以转介血糖控制不佳(HbA ≥ 75mmol/mol(≥9.0%))、存在心理健康和/或社会问题的成年糖尿病患者。在常规护理组中,没有转介途径,从初级保健记录中收集 HbA≥75mmol/mol(≥9.0%)的个体的匿名数据。主要结局是从基线到 12 个月时 HbA 的变化,次要结局是医疗成本和生物医学变量的变化。
3DFD 参与者的血糖控制比对照组差,医疗成本也更高。与对照组相比,3DFD 参与者的血糖控制改善更大[-14mmol/mol(-1.3%)比-6mmol/mol(-0.6%),P<0.001],调整了混杂因素。调整混杂因素后,3DFD 组的总随访医疗成本仍高于对照组(平均差值为 1715 英镑,95%置信区间为 591 至 2811 英镑)。增量成本效益比为 HbA 每降低 1mmol/mol 单位需花费 398 英镑,表明 3DFD 干预措施比常规护理更有效且成本更高。
基于生物医学、心理和社会标准的转介系统,用于识别和管理血糖控制不佳、高成本和高风险的个体,可以改善所有三个维度的健康。